Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of
additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)